Aug. 6 at 7:49 PM
$CNTX If you look at the investors page of CNTX’s website there were no data readouts for 2024 and 2025 outside of preclinical. So not really any catalysts outside of asset purchases and trial dosing. And in those two years the stock was above
$2 for a considerable amount of time. As we get closer to the meaningful data readouts I think the price will run up towards
$1 again and management will just apply for 1 or both of the 180 day extensions if needed.
OVID had 30M cash last year and at
$0.30 still made it on its own to
$1 before any data readouts or PIPE financing.
Biopharma stock screeners will blast the catalysts and it will create buying pressure soon enough. Icing on cake if we get QW data by eoy for CITM-76.
But yeah 2 big catalysts wont go unnoticed and we might get a repeat of this year next year with better outcomes.
